Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies.

Abstract

Potent CD19-directed immunotherapies, such as chimeric antigen receptor T cells (CART) and blinatumomab, have drastically changed the outcome of patients with relapsed/refractory B cell acute lymphoblastic leukemia (B-ALL). However, CD19-negative relapses have emerged as a major problem that is observed in approximately 30% of treated patients. Developing… (More)
DOI: 10.1172/JCI87366

7 Figures and Tables

Topics

  • Presentations referencing similar topics